RecruitingPhase 1Phase 2NCT07479485

MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)

An Open-Label, Multicenter, Phase I/II Study Evaluating MRG006A in Combination With Immune Checkpoint Inhibitors and Targeted Therapy in Patients With Advanced Hepatocellular Carcinoma

Sponsor

Lepu Biopharma Co., Ltd.

Enrollment

160 participants

Start Date

Apr 8, 2026

Study Type

INTERVENTIONAL

Conditions

Hepatocellular Carcinoma

Summary

This is an open-label, multicenter, Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of MRG006A in combination with immune checkpoint inhibitors and targeted therapy in patients with advanced hepatocellular carcinoma (HCC).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Bevacizumab, a drug called MRG006A, and others for people with hepatocellular carcinoma. The study is currently recruiting participants at 8 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMRG006A

Administrated intravenously

DRUGPucotenlimab

Administrated intravenously

DRUGBevacizumab

Administrated intravenously

DRUGPD1/VEGF antibody

Administrated intravenously

DRUGTKI

Administrated intravenously

Locations(8)

Beijing You An Hospital, Capital Medical University

Beijing, Beijing Municipality, China

The Ethics Committee of Cancer Hospital Chinese Academy of Medical Sciences.

Beijing, Beijing Municipality, China

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

Mengchao Hepatobiliary Hospital of Fujian Medical University

Fuzhou, Fujian, China

Henan Cancer Hospital

Zhengzhou, Henan, China

The First Affiliated Hospital With Nanjing Medical University

Nanjing, Jiangsu, China

Tianjin Cancer Hospital Airport Hospital

Tianjin, Tianjin Municipality, China

Lishui Central Hospital

Lishui, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07479485

Related Trials

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

NCT07179900

TARGETed Therapy Drug MONITOring in DIGestive Oncology

NCT0544308729 locations

Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC

NCT049127651 location

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

NCT072850441 location

Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant

NCT070594941 location